BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months. “With our strong financial position and the Board’s commitment to shareholder value, this share re ...

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20. To access a live webcast of the presentation, please visit the Investors ...

BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Compan ...

Lantheus (NASDAQ: LNTH ) is a company with a portfolio of pharmaceutical products important for the detection of diseases and cancers. The company has wide margins and double-digit growth, but recently fell 20% after its Q3 2024 report dueMy name is María Fernanda and I am currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, ...

Financial Data and Key Metrics Changes - Consolidated net revenue for Q3 2024 was $378.7 million, an increase of 18.4% year-over-year [24] - GAAP reported net income for Q3 was $131 million, with adjusted net income at $124.1 million, reflecting a 20.4% increase [28] - Gross profit margin improved to 68.2%, up 109 basis points year-over-year [25] - Operating profit for the quarter was $165.1 million, an increase of 18.3% [26] - Operating cash flow totaled $175.1 million, up $58.3 million from the prior year [29] Business Line Data and Key Metrics Changes - PYLARIFY net sales were approximately $260 million, up 20% year-over-year, but down 5% sequentially [8][24] - DEFINITY delivered Q3 net sales of $77 million, increasing 14% year-over-year [12] - Precision diagnostic revenue was $103.7 million, a 7.7% increase [24] - Strategic partnerships and other revenue rose to $15.3 million, up 108.3% [24] Market Data and Key Metrics Changes - PYLARIFY is on track to grow mid-20% year-over-year in 2024, aiming for blockbuster status with over $1 billion in sales [8][9] - The U.S. market for Alzheimer's radio diagnostics is projected to reach $1.5 billion by the end of the decade and $2.5 billion by the mid-2030s [16] Company Strategy and Development Direction - The company aims to enhance its leadership in radiopharmaceuticals through operational excellence and prudent capital deployment [5] - Focus on expanding the pipeline with innovative product candidates, including radiotherapeutics and Alzheimer's diagnostics [34] - The company plans to pursue thoughtful business development and M&A opportunities [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining PYLARIFY as a $1 billion franchise, despite net price compression due to strategic partnerships [49] - The recent CMS decision to pay separately for specialized diagnostic radiopharmaceuticals is seen as a significant win for patient access and innovation [6][10] - Management remains optimistic about the overall market growth and the potential for PYLARIFY to lead in the PSMA PET imaging market [50] Other Important Information - The company has a strong liquidity position with cash and cash equivalents of $866.4 million and access to a $350 million undrawn bank revolver [29] - The 2027 $575 million convertible debt was reclassified to current liability due to stock price performance [30] Q&A Session Summary Question: Factors behind PYLARIFY's Q3 revenues - Management noted that PYLARIFY grew 20% year-over-year, with sequential decline attributed to seasonality and net price impact from strategic partnerships [37][39] Question: Clarification on CMS reimbursement rates - Management confirmed that the final 2025 payment rate for PYLARIFY matches the existing rate, ensuring sustained access for innovative diagnostics [41][43] Question: Guidance for Q4 and pricing dynamics - Management expects PYLARIFY to improve sequentially in Q4, with R&D expenses driving a step-down in projected earnings [45][46] Question: Confidence in sustaining PYLARIFY as a $1 billion franchise - Management clarified that while they anticipate growth, net price compression from partnerships will have a transitory impact [48][50] Question: Insights on Alzheimer's diagnostic pipeline - Management highlighted the differentiation of their Alzheimer's assets, emphasizing high sensitivity and low off-target binding [64][66]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share LNTH The Nasdaq Global Market Large accelerated filer ☑ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging Growth Company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Septemb ...

Exhibit 99.1 Lantheus Reports Third Quarter 2024 Financial Results • Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023 • GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023 • Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance • Company applauds CMS' C ...

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services’ (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and en ...

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahe ...

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was <1.00 when Assessed Using Two-Stage and In ...